CellOrigin Biotech utilizes induced pluripotent stem cell (iPSC) technology to produce innate immune cells specifically designed for cancer immunotherapy. This method provides a scalable source of immune cells that can effectively target and eliminate tumors, addressing the critical need for more effective immune-based cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer immunotherapies face limitations in scalability and efficacy due to challenges in sourcing and engineering immune cells to effectively target and eliminate tumors. Traditional methods often struggle to produce a consistent and sufficient supply of immune cells with the desired therapeutic properties.
Solution
CellOrigin Biotech leverages induced pluripotent stem cell (iPSC) technology to generate engineered innate immune cells for cancer immunotherapy. Their platform enables the scalable production of immune cells with enhanced tumor-targeting capabilities. By differentiating iPSCs into specific immune cell types, such as NK cells and macrophages, CellOrigin aims to create a readily available and consistent source of therapeutic cells. These cells are genetically modified to improve their ability to recognize, infiltrate, and destroy tumors, offering a more effective and accessible approach to cancer treatment.
Target Audience
The primary target audience includes cancer researchers, clinical trial investigators, and pharmaceutical companies developing novel immunotherapies.
Features
- iPSC differentiation platform for efficient generation of immune cells
- Gene manipulation technology for enhanced tumor-targeting capabilities
- Production of T cells, macrophages, and NK cells from iPSCs
- "Core + Peripheral" patent layout
- Mature stem cell reprogramming technology
- High-efficiency stem cell gene modification technology
- Stem cell directed differentiation technology